Alzheimer's & Dementia Suppliment

Alzheimer's & Dementia Suppliment

Free access
Volume 4, Issue 1, Supplement 1, Pages A1-A8, S1-S168 (January 2008)

Contents Page A3
PDF (39 K)
3. Contents
Page A4
PDF (49 K)
4. Editorial board
Page A5
PDF (36 K)
5. Medical and scientific advisory council
Page A6
PDF (32 K)
Editorial
6. Leon Joel Thal, MD, 1944–2007: Honoring his scientific legacy
Pages S1-S3
Zaven S. Khachaturian
PDF (67 K)
Perspectives
7. Leon Thal and the therapeutic age of Alzheimer’s disease
Pages S4-S6
Paul S. Aisen
PDF (75 K)
8. Chronic disease long-term drug prevention trials: Lessons from the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT)
Pages S7-S14
Curtis L. Meinert, John C.S. Breitner
PDF (130 K)
9. Optimizing phase II of drug development for disease-modifying compounds
Pages S15-S20
Jeffrey L. Cummings
PDF (289 K)
10.
We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer’s disease drug development
Pages S21-S25
Rachelle S. Doody
PDF (89 K)
11. Drug discovery and the prevention of Alzheimer’s disease
Pages S26-S28
Howard Fillit
PDF (79 K)
12. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer’s disease
Pages S29-S36
Norman L. Foster, Angela Y. Wang, Tolga Tasdizen, P. Thomas Fletcher, John M. Hoffman, Robert A. Koeppe
PDF (2125 K)
13. Eyes on the prize: Federal Alzheimer’s research effort aims to facilitate interventions
Pages S37-S47
Richard J. Hodes, Neil Buckholtz, Vicky Cahan, Marcelle Morrison-Bogorad
PDF (159 K)
14. Current and future management of Alzheimer’s disease
Pages S48-S50
Serge Gauthier, Judes Poirier
PDF (77 K)
15. A quarter century of advancing treatment for Alzheimer’s disease with Leon J. Thal
Pages S51-S55
Michael Grundman
PDF (100 K)
16. The oldest old and the 90+ Study
Pages S56-S59
Claudia H. Kawas
PDF (109 K)
17. Home-based technologies: A new paradigm for conducting dementia prevention trials
Pages S60-S66
Jeffrey Kaye
PDF (427 K)
18. Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography
Pages S67-S76
Robert A. Koeppe, Sid Gilman, Larry Junck, Kris Wernette, Kirk A. Frey
PDF (1081 K)
19. Dementia: Is it time for a change in focus?
Pages S77-S84
Lewis H. Kuller, Oscar L. Lopez
PDF (125 K)
20. A perspective on risks that impede development of drugs to modify the course of Alzheimer’s disease: Can they be reduced?
Pages S85-S87
Richard C. Mohs
PDF (82 K)
21. Challenges in clinical research on Alzheimer’s disease: Leon Thal’s legacy
Pages S88-S90
Ronald C. Petersen
PDF (76 K)
22. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer’s disease
Pages S91-S97
Judes Poirier
PDF (314 K)
23. The pre–mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease
Pages S98-S108
Barry Reisberg, Leslie Prichep, Lisa Mosconi, E. Roy John, Lidia Glodzik-Sobanska, Istvan Boksay, Isabel Monteiro, Carol Torossian, Alok Vedvyas, Nauman Ashraf, Imran A. Jamil, Mony J. de Leon
PDF (1881 K)
24. Disease-modifying approaches to Alzheimer’s disease: Challenges and opportunities—Lessons from donepezil therapy
Pages S109-S118
Marwan N. Sabbagh, Sharon Richardson, Norman Relkin
PDF (216 K)
25. Current challenges for the successful treatment and prevention of Alzheimer’s disease: Treating the pathologies of the disease to change its clinical course
Pages S119-S121
Dale Schenk
PDF (69 K)
26. Prevention therapeutics of dementia
Pages S122-S130
Lon S. Schneider
PDF (137 K)
27. More than a decade of estrogen neuroprotection
Pages S131-S136
James W. Simpkins, Meharvan Singh
PDF (129 K)
28. Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer’s disease
Pages S137-S143
Colleen E. Jackson, Peter J. Snyder
PDF (130 K)
29. Memory health clinics—a first step to prevention
Pages S144-S149
Bruno Vellas, Sophie Gillette-Guyonnet, Sandrine Andrieu
PDF (109 K)
30. Leon Thal’s vision for the treatment and prevention of Alzheimer’s disease
Pages S150-S152
Michael W. Weiner
PDF (72 K)
31. Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses
Pages S153-S168
Mehmet Cansev, Richard J. Wurtman, Toshimasa Sakamoto, Ismail H. Ulus
PDF (1100 K)

http://www.sciencedirect.com/science/journal/15525260